Repligen extends Protein A ligand supply deal with GE Healthcare
Protein A is essential in keeping the costs and complexity of purifying monoclonal antibodies down, says GE Healthcare as it extends its supply agreement with Repligen.
Archives for February 26, 2016
Second Vimizim manufacturing site ready mid-2017, BioMarin
BioMarin expects commercial production of its recently approved orphan drug Vimizim (elosulfase alfa) to begin at a secondary facility in Ireland – acquired from Pfizer – mid-2017.